Biologically Active Substance – Page 5

Merck & Co. Partners with Epitopea to Explore ‘Junk DNA’ for Novel Cancer Antigens

2 months ago talkbio0Tagged Cryptigen, CryptoMap platform, DNA, Epitopea, heroin, Immunotherapy, Immunotherapy for cancer, Merck & Co., tumor-specific antigens

Merck & Co., Epitopea, cancer immunotherapy, Cryptigen tumor-specific antigens, CryptoMap platform, junk DNA, off-the-shelf immunotherapies

FDA Approves Ono’s Romvimza for Rare Joint Tumor, Challenging Daiichi Sankyo’s Turalio

2 months ago talkbio0Tagged Approved, CSF1, CSF1 gene, Daiichi, Dosage Forms, Fibrous histiocytoma of tendon sheath, Giant Cell Tumors, Inhibitor, Joint Tumor, Romvimza, Sankyo, tenosynovial, Turalio, United States Food and Drug Administration, Vimseltinib

Romvimza, vimseltinib, tenosynovial giant cell tumor (TGCT), Ono Pharmaceutical, FDA approval, Daiichi Sankyo, Turalio, CSF1 inhibitor, rare joint tumor

Arcus Biosciences Advances Promising Kidney Cancer Drug Casdatifan After Gilead Opts Out

2 months ago talkbio0Tagged Arcus, casdatifan, cell renal cell carcinoma, Clinical Trials, Conventional (Clear Cell) Renal Cell Carcinoma, HIF-2a, Inhibitor, Malignant neoplasm of kidney

Arcus Biosciences, casdatifan, HIF-2a inhibitor, kidney cancer, clear cell renal cell carcinoma (ccRCC), Gilead Sciences, clinical trial data, $150 million stock offering

Septerna Halts Phase 1 Trial of SEP-786 Due to Unexpected Bilirubin Elevations

2 months ago talkbio0Tagged Agonist, Bilirubin, Clinical Trials, Discontinuation (procedure), Hypoparathyroidism, PTH1R gene, SEP-786, Septerna

Septerna, SEP-786, clinical trial discontinuation, hypoparathyroidism, bilirubin elevation, PTH1R agonist, biotech setback

Bristol Myers Squibb’s Opdualag Fails Phase 3 Trial in Adjuvant Melanoma Treatment

2 months ago talkbio0Tagged Clinical Trials, Failure (biologic function), Immunologic Adjuvants, Immunotherapy, Inhibitor, lymphocyte-activation gene 3 protein, human, melanoma, Myers, Opdualag, squibb

Opdualag, Bristol Myers Squibb, melanoma, clinical trial failure, LAG-3 inhibitor, immunotherapy, adjuvant treatment

Pfizer’s Talzenna-Xtandi Combo Shows Significant Survival Benefit in Advanced Prostate Cancer

2 months ago talkbio0Tagged Clinical Trials, Gene Mutation, Inhibitor, Metastatic castration-resistant prostate cancer, Overall Survival, PARP1 gene, recombinational repair, TALAPRO-2, Talzenna, Xtandi

Talzenna, Xtandi, metastatic castration-resistant prostate cancer (mCRPC), overall survival, TALAPRO-2 trial, PARP inhibitor, homologous recombination repair (HRR) gene mutations

Semaglutide Shows Promise in Reducing Alcohol Consumption, Small Study Reveals

2 months ago talkbio0Tagged addiction, Alcohol Use Disorder, Craving for alcohol, Glucagon-Like Peptide 1, semaglutide, Wegovy, Weight Loss Medication

semaglutide, Ozempic, Wegovy, alcohol use disorder, GLP-1 drugs, alcohol cravings, weight loss medication, addiction treatment

Axplora Invests €50M in GLP-1 Manufacturing Expansion at Mourenx, France

2 months ago talkbio0Tagged alpha 1-antitrypsin, Axplora, biology (field), CDMO, Chromatography, Diabetes, expansion, France, Glucagon-Like Peptide 1, Manufacturing, Mourenx, Obesity, production

Axplora, GLP-1, manufacturing expansion, Mourenx, France, CDMO, API production, chromatography, diabetes, obesity, biologic therapies

SpringWorks Therapeutics Secures FDA Approval for Gomekli to Treat NF1-Related Tumors

2 months ago talkbio0Tagged Approved, disease treatment, Gomekli, Infrequent, Inhibitor, MEK, mirdametinib, Neurofibromatosis 1, Plexiform, Plexiform Neurofibroma, SpringWorks, United States Food and Drug Administration

SpringWorks Therapeutics, Gomekli, mirdametinib, FDA approval, neurofibromatosis type 1 (NF1), plexiform neurofibromas (PN), rare disease treatment, MEK inhibitor

AnaptysBio’s Rosnilimab Shows Promising Results in Phase 2b Rheumatoid Arthritis Trial

2 months ago talkbio0Tagged Agonist, AnaptysBio, Autoimmune Diseases, Immunoregulation, PDCD1 gene, Rheumatoid Arthritis, Rosnilimab

Rosnilimab, PD-1 agonist, rheumatoid arthritis, Phase 2b trial, immune modulation, AnaptysBio, autoimmune disease